Analyst Price Target is $26.14
▲ +263.60% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for ProQR Therapeutics in the last 3 months. The average price target is $26.14, with a high forecast of $44.00 and a low forecast of $17.00. The average price target represents a 263.60% upside from the last price of $7.19.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in ProQR Therapeutics. This Buy consensus rating has held steady for over two years.
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer, and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.